This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shin, A. Articles by Zheng, W. Search for Related Content PubMed PubMed Citation Articles by Shin, A. Articles by Zheng, W.

Genetic Polymorphisms of the Transforming Growth Factor-ß1 Gene and Breast Cancer Risk: A Possible Dual Role at Different Cancer Stages

¹ Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee and ² Department of Epidemiology, Shanghai Cancer Institute, Shanghai, China

Requests for reprints: Wei Zheng, Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Vanderbilt University Center for Health Services Research Suite 6000, Medical Center East, Nashville, TN 37232-8300. Phone: 615-936-0682; Fax: 615-936-1269. E-mail: wei.zheng@vanderbilt.edu

Transforming growth factor-ß (TGF-ß) inhibits the proliferation of carcinomas in early stages of breast cancer, whereas it promotes tumor growth and metastasis in later stages of cancer. We evaluated a possible association between TGF-ß1 gene polymorphisms and breast cancer risk in a population-based case-control study of Chinese women living in Shanghai, which included 1,127 breast cancer cases and 1,228 population controls. Two polymorphisms, C-509T and T+29C, were in strong linkage disequilibrium. There were no overall differences in the genotype distribution of T+29C polymorphisms of the TGF-ß1 gene among cases and controls. However, the distribution of the high-activity C allele of T+29C polymorphisms differed by cancer stages (P_trend = 0.02). This allele was associated with decreased risk of early-stage breast cancer [stages 0 and I; odds ratio (OR), 0.73; 95% confidence interval (95% CI), 0.54-0.99], and the OR was further reduced to 0.66 (95% CI, 0.45-0.96) for those homozygous for this allele (P_trend = 0.03). On the other hand, the same allele was associated with nonsignificantly increased risk of breast cancer with advanced stages III and IV (OR, 1.33; 95% CI, 0.81-2.18), which differed significantly from that observed for early-stage cancer (P = 0.04). This result suggests a possible dual effect of TGF-ß1 shown by in vitro experiments and provides an explanation for some of the inconsistent findings from previous epidemiologic studies that did not evaluate this association by cancer stage.

This article has been cited by other articles:

				J. P. A. Ioannidis Common genetic variants for breast cancer: 32 largely refuted candidates and larger prospects. J Natl Cancer Inst, October 4, 2006; 98(19): 1350 - 1353. [Full Text] [PDF]

				H. S. Feigelson, A. V. Patel, W. R. Diver, V. L. Stevens, M. J. Thun, and E. E. Calle Transforming Growth Factor {beta} Receptor Type I and Transforming Growth Factor {beta}1 Polymorphisms Are Not Associated with Postmenopausal Breast Cancer. Cancer Epidemiol. Biomarkers Prev., June 1, 2006; 15(6): 1236 - 1237. [Full Text] [PDF]

				J.-H. Mao, E. F. Saunier, J. P. de Koning, M. M. McKinnon, M. N. Higgins, K. Nicklas, H.-T. Yang, A. Balmain, and R. J. Akhurst Genetic variants of Tgfb1 act as context-dependent modifiers of mouse skin tumor susceptibility PNAS, May 23, 2006; 103(21): 8125 - 8130. [Abstract] [Full Text] [PDF]